Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms.

Trial Profile

COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms.

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Voclosporin (Primary)
  • Indications Angina pectoris; Asymptomatic myocardial ischaemia; Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms CONFIRM-1
  • Sponsors Atrium Medical Corporation

Most Recent Events

  • 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
  • 01 Oct 2010 Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 Scientific Symposium, according to an Isotechnika Pharma media release.
  • 22 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by Isotechnika.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top